Tag Archives: Immunoprotein Diagnostic Testing Market

Immunoprotein Diagnostic Testing Market Driven By Increasing Popularity of Chemiluminescence Assay Technology

Global Immunoprotein Diagnostic Testing Market: Snapshot

Immunoprotein is a protein with immunological activity. When in an unhealthy state, they display an abnormal increase in their blood concentration, thus acting as a potential indicator for disease diagnosis. The market of global immunoprotein diagnostic testing is on an upswing owing to a large pool of geriatrics and high occurrence of chronic diseases.

The incidence of various infectious diseases is multiplying and a large section of the population in developing economies is suffering due to unhygienic conditions and illiteracy. Many are reportedly succumbing to malaria and cancer, hence early diagnosis is high in demand. This is where immunoprotein diagnostic testing comes in handy. As new and innovative technologies are being continuously introduced in the market, the shelf life of the products is shrinking, thereby acting as a hindrance for market players.

Read Full Report: http://www.transparencymarketresearch.com/immunoprotein-diagnostic-testing.html

According to Transparency Market Research, the global immunoprotein diagnostic testing market is estimated to reach US$15.3 bn by 2019.

Expensive Radioimmunoassay to Trail Other Assay Market Segments

Based on technology, chemiluminescence assay is a rapidly growing segment and growth of this market can be attributed to a wide scope of application, increased sensitivity, and ease of use. Fuelled by the development of multiple ELISA technologies, the ELISA market is expected to grow in a significant manner. On the contrary, the radioimmunoassay segment is expected to lose its footing in the market due to government restrictions on the use of radioactive substances and high cost of assay equipment and safety devices. In addition, the segment will experience a downfall as better and safer technologies such as chemiluminescence assay, ELISA, and immunofluorescence assay will replace radioimmunoassay soon. Immunofluorescence and immunoturbidity assay segments are expected to grow at a modest CAGR of about 5% during the forecast period.

The application of immunoprotein diagnostic testing can be found in infectious diseases, oncology testing, endocrine testing, toxicology testing, allergy testing, and autoimmune disease testing. Oncology testing is projected to account for a large market share in the forecast period. Commoditization of products, growing demand for quick, accurate, and preventive healthcare, especially in emerging economies, technological developments, expansions in the field of immunochromatography, and strengthening network of distributors at a global level will contribute to the market growth – generating maximum revenue of US$4,943.0 mn by 2019.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1253

High Prevalence of Chronic Diseases to Push Sales in the U.S.

The immunoprotein diagnostic testing market is geographically segmented into North America, Europe, Asia Pacific, and Rest of the World. High incidence of chronic and infectious diseases, shift to POC rapid diagnostic tests, laboratory automation, and increased FDA approval for new products are some of the key factors that have led North America to dominate the said market. According to the report, this region is projected to continue enjoying its top position in the forecast period as well.

Developing economies of Asia Pacific are also expected to contribute to the market growth in the years to come. Better healthcare facilities, increase in disposable income, improving literacy rate, and growing awareness about major infectious and chronic diseases are few of the factors that are fuelling the demand for immunoprotein diagnostic testing in this region.

Roche, Abcam PLC, Diasorin, Enzo Life Sciences, Abbott Laboratories, Randox Laboratories, Siemens, The Binding Site, and Thermo Fisher Scientific are some of the prominent players in the global immunoprotein diagnostic testing market.

 

Advertisements

Discovery of New Biomarkers to Expand Scope of Immunoprotein Diagnostic Testing, reports TMR

Immunoproteins play a pivotal role in executing an immune response against foreign material in the body. Although the concentration of these proteins is at minimal levels at normal conditions, the levels increase 10 to 100 fold upon exposure to antigens. Various immunoproteins such as immunoglobulins, C reactive proteins, haptoglobin, prealbumin, free light chains and complement system proteins which mainly include C3 and C4 proteins are targeted for diagnosis of diseased condition.

Read Full Report: http://www.transparencymarketresearch.com/immunoprotein-diagnostic-testing.html

Concentration of these proteins can be determined using technological platforms such as radioimmunoassay, enzyme based immunoassay, chemiluminescence assay, immunofluorescence assay, immunoturbidity assay, and immunoprotein electrophoresis. According to Transparency Market Research (http://www.transparencymarketresearch.com/), a leading U.S.-based market research firm, the global immunoprotein diagnostic testing market was valued at USD 11,019.7 million in 2012 and is expected to grow at a CAGR of 5.7% from 2013 to 2019, to reach an estimated value of USD 15,351.0 million in 2019.

With the rising incidences of diseases such as cancer, diabetes, tuberculosis, malaria, and various viral infections, quick and confirmed diagnosis has been a prime need in hospitals and diagnostic centers worldwide. The rapid aging population will increase the number of individuals requiring medical attention in the near future exponentially. Moreover, prevalence of allergies and autoimmune diseases whose diagnosis is even more critical are also on the rise. This has increased the demand for accurate and quick diagnostic tests. To cater this need, biotechnology companies have developed rapid tests based various technology platforms for the diagnosis of infectious diseases, allergies, autoimmune diseases, cancers, and hormone related disorders.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1253

Chemiluminescence assays (CLIA) are becoming increasingly popular owing to accuracy and simple procedure. In Chemiluminescence assays, luminescence is produced by chemical reaction as against Enzyme linked Immunosorbent Assay (ELISA) in which enzyme reaction products visible color. CLIA assays technology has also been employed in infectious disease testing, allergy testing, autoimmune disease testing, growth deficiency identification and cancer screening. Multiplex CLIA have also hit the market where in multiple analytes can be tested in a single assay cycle. CLIA technology has deep market penetration and is currently growing at a CAGR of 6.4% globally. The market growth is however restrained because of the resistance to upgrade technology especially in developing nations. Laboratory technicians are trained for ELISA procedures, whileexisting base of ELISA readers in hospitals and diagnostic laboratories has increased the cost of switching.

Key players in the immunoprotein diagnostic testing market are Abbott Laboratories, Siemens Healthcare, DiaSorin, The Binding Site, Roche Diagnostics, Randox Laboratories and Thermo Fisher Scientific.

Immunoprotein Diagnostic Testing Market: Aggressive Research Activities Stimulating Market Growth

The global immunoprotein diagnostic testing market is led by many global giants. Some of the players operating in the market are Abbott Laboratories, Inc., Abcam PLC, Enzo Life Sciences, Inc., DiaSorin SPA, and Fujirebio Diagnostics, Inc. The distributors in the market, supply products for more than one company. A few substitutes in the market such as molecular diagnostics and microbiology assay are available, but with their own disadvantages. Thus, the threat of substitutes is expected to be low, states a new report by Transparency Market Research (TMR).

High entry barriers such as compliance to regulations and huge capital requirements exist in the immunoprotein diagnostic testing market. However, the threat of new entrants is still expected to be moderate as many new players offer OEM services to the leading players in the market. These small companies can enter the market easily through forward integration.

Read Full Report: http://www.transparencymarketresearch.com/immunoprotein-diagnostic-testing.html

According to the report, the global immunoprotein diagnostic testing market is expected to be worth US$15.35 bn by 2019. On the basis of assay technology used, the enzyme-based immunoassay segment is expected to lead in the market in the coming years. The market for enzyme-based immunoassay is projected to be worth US$5.34 bn by 2019.

North America to Lead Market owing to Need for Quick Diagnostic Services for Viral Infections and Cancer

By geography, North America is expected to lead in the market and be worth US$6.07 bn by 2019. The market in the region is driven by the demand for quick diagnostic services for viral infections and cancer. The rising trend of preventive healthcare is also creating new opportunities for the market in North America. Additionally, increasing cases of drug abuse and allergies have become major concerns in the U.S., which are further driving the demand for immunoprotein diagnostic testing.

By immunoprotein type, the immunoglobulin diagnostic tests segment is expected to lead in the global market in the coming years. The global market for immunoglobulin diagnostic testing is expected to be worth US$4.7 bn by 2019 owing to a wide scope of application in infectious disease testing, allergy testing, and autoimmune testing.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1253

Rising Prevalence of Diseases to Create Need for Immunoprotein Diagnostic Testing

The rising prevalence of malaria, hepatitis, typhoid, HIV, tuberculosis, and cancer across the globe is driving the global immunoprotein diagnostic testing market. “Many of the diseases have a higher prevalence in underdeveloped economies,” states a TMR analyst. Thus, the demand for low cost, yet effective diagnostic tests is particularly high in underdeveloped nations. A need to diagnose diseases at an earlier stage to avoid severe complications is leading to an increased demand for immunoprotein diagnostic testing kits. Besides this, the market is gaining impetus from technological innovations. Advancements in technology have helped reduce the amount of sample required for tests and also enabled testing for multiple biomarkers in a single assay, reducing the cost per test.

High Cost of Diagnosis Dampening Demand for Immunoprotein Diagnostic Testing

Due to economic crisis, governments of countries such as Germany, France, Spain, Italy, and Hungary have cut down on reimbursement rates, which is increasing the out of pocket expenses of patients. This is limiting the adoption of immunoprotein diagnostic testing. Additionally, the low per capita income of people in many countries have led patients to look for cost effective alternatives for diagnosis. These factors are expected to dampen the demand for immunoprotein diagnostic testing.

Immunochromatography-based Cassette Kits to Emerge as Opportunity for Growth in Market

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1253

After the modification of the Clinical Laboratory Improvement Amendments (CLIA) waiver policies, the FDA has approved tests for home use. This has hugely benefitted the home diagnostics market, which is led by immunochromatography-based cassette kits such as pregnancy detection kits, HIV, malaria, and drug abuse testing kits. Additionally, the over-the-counter sale and wide availability of immunochromatography-based cassette kits are expected to drive the market further.

An increased investment in R&D in order to expand the application of the available technologies have led to the introduction of newer products. This has also led to the discovery of new biomarkers such as free light chains, which is acting as an opportunity to expand the scope of market.

This information is based on the findings of a report published by Transparency Market Research titled “Immunoprotein Diagnostic Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2019.”

 

Immunoprotein Diagnostic Testing Market Outlook and Forecast up to 2019

The global immunoprotein diagnostic testing market is led by many global giants. Some of the players operating in the market are Abbott Laboratories, Inc., Abcam PLC, Enzo Life Sciences, Inc., DiaSorin SPA, and Fujirebio Diagnostics, Inc. The distributors in the market, supply products for more than one company. A few substitutes in the market such as molecular diagnostics and microbiology assay are available, but with their own disadvantages. Thus, the threat of substitutes is expected to be low, states a new report by Transparency Market Research (TMR).

High entry barriers such as compliance to regulations and huge capital requirements exist in the immunoprotein diagnostic testing market. However, the threat of new entrants is still expected to be moderate as many new players offer OEM services to the leading players in the market. These small companies can enter the market easily through forward integration.

According to the report, the global immunoprotein diagnostic testing market is expected to be worth US$15.35 bn by 2019. On the basis of assay technology used, the enzyme-based immunoassay segment is expected to lead in the market in the coming years. The market for enzyme-based immunoassay is projected to be worth US$5.34 bn by 2019.

North America to Lead Market owing to Need for Quick Diagnostic Services for Viral Infections and Cancer

By geography, North America is expected to lead in the market and be worth US$6.07 bn by 2019. The market in the region is driven by the demand for quick diagnostic services for viral infections and cancer. The rising trend of preventive healthcare is also creating new opportunities for the market in North America. Additionally, increasing cases of drug abuse and allergies have become major concerns in the U.S., which are further driving the demand for immunoprotein diagnostic testing.

By immunoprotein type, the immunoglobulin diagnostic tests segment is expected to lead in the global market in the coming years. The global market for immunoglobulin diagnostic testing is expected to be worth US$4.7 bn by 2019 owing to a wide scope of application in infectious disease testing, allergy testing, and autoimmune testing.

Rising Prevalence of Diseases to Create Need for Immunoprotein Diagnostic Testing

The rising prevalence of malaria, hepatitis, typhoid, HIV, tuberculosis, and cancer across the globe is driving the global immunoprotein diagnostic testing market. “Many of the diseases have a higher prevalence in underdeveloped economies,” states a TMR analyst. Thus, the demand for low cost, yet effective diagnostic tests is particularly high in underdeveloped nations. A need to diagnose diseases at an earlier stage to avoid severe complications is leading to an increased demand for immunoprotein diagnostic testing kits. Besides this, the market is gaining impetus from technological innovations. Advancements in technology have helped reduce the amount of sample required for tests and also enabled testing for multiple biomarkers in a single assay, reducing the cost per test.

High Cost of Diagnosis Dampening Demand for Immunoprotein Diagnostic Testing

Due to economic crisis, governments of countries such as Germany, France, Spain, Italy, and Hungary have cut down on reimbursement rates, which is increasing the out of pocket expenses of patients. This is limiting the adoption of immunoprotein diagnostic testing. Additionally, the low per capita income of people in many countries have led patients to look for cost effective alternatives for diagnosis. These factors are expected to dampen the demand for immunoprotein diagnostic testing.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1253

Immunochromatography-based Cassette Kits to Emerge as Opportunity for Growth in Market

After the modification of the Clinical Laboratory Improvement Amendments (CLIA) waiver policies, the FDA has approved tests for home use. This has hugely benefitted the home diagnostics market, which is led by immunochromatography-based cassette kits such as pregnancy detection kits, HIV, malaria, and drug abuse testing kits. Additionally, the over-the-counter sale and wide availability of immunochromatography-based cassette kits are expected to drive the market further.

An increased investment in R&D in order to expand the application of the available technologies have led to the introduction of newer products. This has also led to the discovery of new biomarkers such as free light chains, which is acting as an opportunity to expand the scope of market.

This information is based on the findings of a report published by Transparency Market Research titled “Immunoprotein Diagnostic Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2019.”